Hokuriku Pharmaceutical announced that the company participated in the 12th batch of centralized procurement of national pharmaceuticals. The product pioglitazone metformin is to be selected for oral regular release dosage. The declared product regulations are 15 mg of pioglitazone hydrochloride and 500 mg of metformin hydrochloride per tablet. The procurement period starts from the date of implementation of the selection results to December 31, 2029.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.